Commentary · 8 Oct 2025
Mini reviewPublished 11 May 2022
Human ?-Galactosidase: Safety, Efficacy and Molecular Basis of Pharmacological Chaperoning
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Fabry infection patients show a lack in the action of the lysosomal catalyst α-galactosidase (α-GAL or α-Gal A). One proposed treatment for Fabry infection is pharmacological chaperone treatment, where a little atom balances out the α-GAL protein, prompting expanded enzymatic movement. Utilizing protein energy, tryptophan fluorescence, roundabout dichroism, and proteolysis measures, we show that the pharmacological chaperones 1-Deoxygalactonojirimycin (DGJ) and galactose settle the human α-GAL glycoprotein. Gem designs of buildings of α-GAL and chaperones make sense of the sub-atomic reason for the higher strength of DGJ over galactose. Utilizing site-coordinated mutagenesis, we show the higher intensity of DGJ results from an ionic communication with D170. We recommend that protonation of D170 in acidic circumstances prompts more fragile restricting of DGJ. The outcomes lay out a biochemical reason for pharmacological chaperone treatment pertinent to other protein misfolding sicknesses.
Keywords
Subjects
Pathology & Lab MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Annals of Clinical and Laboratory Research.
Mini review · 2 Oct 2025
Characteristics and Treatment of Juvenile Myasthenia Gravis
Commentary · 9 Jul 2025
Commentary on Upadacitinib in Difficult-to-Treat Psoriatic Arthritis: Real-World Data from 134 Patients
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalAnnals of Clinical and Laboratory Research
- SubjectPathology & Lab Medicine
- BylineArticles whose byline prints “Nathaniel Garman”
